We’re thrilled to announce that our research team at the University of Catania is on the front page of #UnictMagazine with a groundbreaking new study on the #JollyVaccine! In this pioneering study, we’ve worked tirelessly to develop an innovative solution to address the challenges associated with vaccination, focusing on the concept of a “Jolly Vaccine.”…
Read more
Article: ‘Sviluppare un vaccino influenzale universale simulanndo gli anticorpi’ In the latest edition of #LaSicilia, a groundbreaking study has been highlighted, shedding light on the development of a universal influenza vaccine through the simulation of antibodies. Conducted by the esteemed research team led by Prof. Francesco Pappalardo at the #CombineGroup, this study has immense implications…
Read more
In the ever-evolving landscape of medical research and technology, advancements often go unnoticed until they reach a critical mass of recognition. However, for the Universal Immune System Simulator (UISS), developed by Professor Francesco Pappalardo and his team, that recognition has arrived in a flurry of attention from seven prestigious newspapers. This marks a significant milestone…
Read more
Uniting the In Silico Community: Insights from the Workshop on Regulatory Barriers in Catania In the serene ambiance of the Monastero dei Benedettini in Catania, the annual gathering of the In Silico community took place on March 14-15. The workshop, titled “The Regulatory Barriers to In Silico Trials,” served as a pivotal platform for experts…
Read more
We take immense pride in presenting the application brief for #tuberculosis treatment, “TBValid collection: Tuberculosis data,” utilizing UISS-TB, an in silico trial solution employing agent-based modeling. “The creation of a synthetically generated, fully anonymized data collection from real-world sources is pivotal for advancing in silico trials targeting crucial factors in silico trials of antivancing in…
Read more
The Combine Group is delighted to announce our involvement in yet another project funded under the Horizon Europe Program: Novel Immunotherapies for Tuberculosis and other Mycobacterial Diseases (ITHEMYC) ???? This venture is a significant opportunity to apply innovative solutions in silico modelling to facilitate both in vitro and in vivo preclinical progression and predict the…
Read more
Evading or minimizing animal testing, expediting drug approval processes, and navigating research pitfalls are the focal points of a team of researchers from the University of Catania, utilizing Uiss, the virtual patient. Uiss, an acronym for Universal Immune System Simulator, represents the culmination of fifteen years of work by Catania’s scientists and fits seamlessly into…
Read more
The diphtheria-tetanus-pertussis vaccine may have beneficial effects by against Sars-CoV-2 and Covid-19 disease. The study was carried out, using the immune system simulator called Universal Immune System Simulator (UISS), by the ‘Combine’ research group directed by Prof. Francesco Pappalardo of the Department of Drug and Health Sciences at the University of Catania and was recently…
Read more
Today the COMBINE group releases as open-source (under Apache License v2.0) the main core of UISS in silico trial platform. You can find the source code following this link: https://www.combine-group.org/assets/attachment/UISS_free.tgz
Antibodies therapeutics are unable to protect patients with severe SARS-CoV-2 infection. This is the study conclusion by the COMBINE group of the University of Catania and published in the prestigious scientific journal BMC Bioinformatics. “The study had been carried out during the COVID-19 emergency in the spring of last year and demonstrates the partial ineffectiveness…
Read more